Your PSMA PET Scan Came Back Negative or Very Faint — What to Do When Lu-177 PSMA Isn't an Option

When the Scan Result Changes Your Treatment Path

You came into the scan appointment hoping for a clear answer. Instead, the report says your PSMA PET scan is negative or very faint. Now you wonder: does this mean Lu-177 PSMA therapy is not an option? What comes next?

This is a common moment of confusion for men with metastatic castration-resistant prostate cancer (mCRPC). A negative or low-signal PSMA PET scan does not mean your cancer is gone. It means the cancer cells in your body may not have enough PSMA protein on their surface for Lu-177 PSMA to reach them. That is a biology question.

This article explains what a low or negative PSMA PET result means, why it happens, and what options your team may still have. For more on who qualifies for Lu-177 PSMA, see our plain-language eligibility guide for men with mCRPC.

What PSMA Expression Means — and Why It Matters

PSMA stands for prostate-specific membrane antigen. It is a protein found on the surface of most prostate cancer cells. The higher the PSMA expression, the more effectively a radioligand drug like Lu-177 PSMA can find and attach to those cells.

A PSMA PET scan uses a radioactive tracer — usually Gallium-68 PSMA or F-18 PSMA — to show where this protein is present. Doctors measure how brightly each area glows, comparing it to the signal from the liver as a reference point.

To qualify for Lu-177 PSMA therapy in most programs, you need at least one lesion that glows brighter than the liver. You also must not have lesions with no uptake at all. These were core requirements in the VISION trial, which led to FDA approval of lutetium vipivotide tetraxetan (Pluvicto) for mCRPC. When a scan comes back negative or very faint, these thresholds were not met.

How Common Is a Negative or Low PSMA Result in mCRPC?

You are not alone. The VISION trial showed that roughly 12 to 13 percent of men screened were excluded because their PSMA PET scan did not reach the required uptake levels. In other trial populations, between 15 and 30 percent of patients had lesions that did not show strong PSMA signal.

Discordant disease is an important pattern in research. This occurs when some lesions in your body show PSMA and others do not. The PSMA-negative lesions often light up on FDG PET, which measures how actively cancer cells use sugar rather than detecting PSMA protein. Research shows these patients often have more aggressive disease, according to studies of PSMA-negative mCRPC outcomes. This pattern matters because it affects which treatments are most likely to help.

Before Accepting the Result: Ask These Questions First

A report that says no significant PSMA uptake does not always close the door permanently. Before concluding that Lu-177 PSMA is not available to you, ask your team the following:

• Which PSMA tracer was used? Gallium-68 PSMA-11 and F-18 PSMA-1007 can give different signal strengths for the same lesion.
• Was the scan read by a nuclear medicine specialist with PSMA experience, or by a general radiologist?
• Were any lesions borderline — close to but not quite meeting the liver uptake threshold?
• Could a change in your current hormonal therapy affect PSMA expression before a repeat scan?

A second opinion from a nuclear medicine specialist or a tumor board with radioligand therapy experience can sometimes give a different reading. Our article on what to do when you are denied Lu-177 PSMA therapy walks through this process in detail, including how to request a specialist scan review.

Your Treatment Options When PSMA Expression Is Low

If your PSMA PET genuinely does not qualify you for Lu-177 PSMA, your oncologist still has meaningful options. The right path depends on your prior treatments, your health status, and your specific cancer biology. Below are the main options your team may discuss.

Taxane-Based Chemotherapy

Taxane chemotherapy may be recommended for men with mCRPC who have progressed on hormonal therapies and whose tumors lack sufficient PSMA expression. Taxanes work by disrupting how cancer cells divide — a way that does not depend on PSMA expression. Your oncologist can assess whether this approach is appropriate for your health status, prior treatments, and goals.

PARP Inhibitors for Certain DNA Repair Mutations

Some prostate cancers carry mutations in DNA repair genes, most notably BRCA1, BRCA2, and ATM. If you have not been tested for these mutations, testing may matter for your next treatment choice. PARP inhibitors have shown clinical benefit in mCRPC patients who carry BRCA1 or BRCA2 mutations, as shown in the PROfound trial and in regulatory assessments of olaparib for this population. These drugs work independently of PSMA expression. If your tumor has not had genomic testing, ask your oncologist about it. The results may reveal treatment options you would not see otherwise.

Radium-223 for Bone-Predominant Disease

If your cancer has spread mainly to the bones with little or no spread to soft tissue or major organs, radium-223 may be worth discussing. This is an alpha-emitting radiopharmaceutical that targets bone metastases directly. Unlike Lu-177 PSMA, it does not require PSMA expression. It is approved for men with bone-predominant mCRPC without known visceral metastases. The Prostate Cancer Foundation provides an overview of approved systemic options for castration-resistant prostate cancer, including radium-223 and other agents.

Androgen Receptor Pathway Options

Depending on which hormonal therapies you have already had, there may be options you have not explored. Your oncologist can review your treatment history and assess whether switching to a different agent in this class makes sense. This depends on your individual situation and which drugs you have already used.

Clinical Trials Designed for PSMA-Low or PSMA-Negative Disease

New clinical trials are studying treatments for PSMA-low and PSMA-negative mCRPC. Several trials examine new radioligand approaches, combination strategies, and novel agents specifically for patients whose disease does not express sufficient PSMA. Asking your team about clinical trial eligibility is one of the most productive steps you can take. Your specialists can help you search the National Cancer Institute clinical trials database for studies that match your disease and treatment history.

Could Your PSMA Expression Change Over Time?

In some patients, PSMA expression is not permanently low. Some hormonal therapy changes may increase the amount of PSMA protein on cancer cell surfaces, which could improve a future scan. This is not guaranteed. Do not delay other treatments while waiting for this. But it is a conversation worth having with a specialist who understands how tumor biology and PSMA expression change over the course of mCRPC.

It is also worth asking whether an FDG PET scan could help. An FDG PET can reveal lesions that a PSMA PET misses, creating a more complete picture of how aggressively different parts of your cancer are behaving. This information can shape treatment planning.

The Case for a Specialist Review at This Stage

When your usual treatment options seem limited, ask about a second opinion or tumor board review. A center with dedicated theranostics and radioligand therapy expertise may help.

Specialists see more PSMA scan variations than general oncologists. They know more about borderline cases and when a rescan might help. They also know more about trials and access pathways for patients in your situation.

If you are uncertain whether your current treatment plan is the best sequence — or whether Lu-177 PSMA could still help later — the article on weighing Lu-177 PSMA against standard-of-care options after hormone resistance covers how oncologists think through this decision.

What International Patients Should Know

If you are traveling from the United Kingdom, United States, Australia, Canada, the UAE, or another country and have received a negative or inconclusive PSMA PET report, the most important step is to share your scan images and written report with a specialist team before assuming your options are gone.

Scan interpretation standards and reporting language differ across countries and institutions. A report written in one healthcare system may use different language than the eligibility criteria at another center. A specialist review can clarify whether your scan truly disqualifies you or if the original reading was too cautious.

Even if your PSMA PET result is confirmed as ineligible, specialist centers in India with international patient programs can help you and your home oncologist understand which other therapies may work. Many Indian cancer institutions have international accreditation and extensive experience with complex mCRPC cases.

Keeping the Door Open

A negative PSMA PET scan is biological information. It is not a final verdict on what is possible for you. Your cancer has genomic mutations, behavior patterns, and tumor spread that all affect treatment options.

The most helpful approach is to get a full picture of your disease, hear from multiple specialists, and check for new clinical trials. New mCRPC treatments are being developed. Patients who initially were not candidates for radioligand therapy may become eligible as evidence changes.

When to Talk to Your Doctor

Contact your oncology team promptly if your PSMA PET has returned negative or very faint and you have not had a detailed conversation about next steps. Ask specifically about genomic testing for BRCA and other DNA repair mutations, FDG PET imaging, clinical trial eligibility, and whether a second scan review or referral to a theranostics specialist is appropriate. Do not wait for a routine appointment if your PSA is rising or your symptoms are changing.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.